{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:25:46Z","timestamp":1779110746429,"version":"3.51.4"},"reference-count":53,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This meta\u2010analysis aimed to explore the impact of biologics on the development of cardiovascular events (CEs) in patients with ankylosing spondylitis (AS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected literature related to the effects of biologics on CEs in AS patients through computerized searches of Embase, Web of Science, PubMed, and the Cochrane Library, as well as manual searches. The literature retrieval spanned from the inception of these databases up to March 28, 2025. Literature selection and data extraction were performed in accordance with predefined eligibility criteria. The Newcastle\u2010Ottawa Scale and the Cochrane Risk of Bias tool for randomized trials were utilized to evaluate the quality of eligible articles. Data analysis was performed using STATA 15.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This meta\u2010analysis incorporated 23 eligible articles encompassing 92\u2009623 subjects. The results illustrated that the biologics group had a lower overall CE risk than the non\u2010biologics group (RR\u2009=\u20090.61, 95% CI, 0.44\u20130.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Specifically, the biologics group demonstrated a reduced risk of myocardial infarction (RR\u2009=\u20090.42, 95% CI, 0.27\u20130.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and ischemic heart disease (RR\u2009=\u20090.09, 95% CI, 0.04\u20130.17,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, there were no significant differences in the risk of heart failure between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). There was no statistically significant variation in the occurrence of CEs between the two groups with the use of etanercept, ixekizumab, or golimumab (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Overall, biologic use may mitigate the risk of CEs, particularly impacting IHD and MI. Given the limitations inherent in the current body of research, additional large randomized controlled trials examining other CE subtypes and specific drug effects are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Not applicable<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1756-185x.70573","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T03:40:37Z","timestamp":1770867637000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Biologics on Cardiovascular Events in Ankylosing Spondylitis: A Meta\u2010Analysis"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7069-251X","authenticated-orcid":false,"given":"Huijiao","family":"Yin","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology Department Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqin","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Department Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Changxing People's Hospital  Huzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"e_1_2_15_2_1","volume-title":"StatPearls","author":"Wenker K. J.","year":"2025"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151191"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113709"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-024-01170-9"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00248-x"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24492"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead072"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000881"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211032444"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221122401"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket454"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216653"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001419"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000786"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02753-6"},{"issue":"20","key":"e_1_2_15_20_1","first-page":"4431","article-title":"Impact of TNF\u2010\u03b1 Inhibitor Therapy on Cardiovascular Outcomes in Ankylosing Spondylitis: A Nationwide Population\u2010Based Study","volume":"28","author":"Nam S. W.","year":"2024","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07225-7"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"e_1_2_15_28_1","first-page":"3534","article-title":"Long\u2010Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2\u2010Year Results From Two Phase 3 Studies","volume":"64","author":"Baraliakos X.","year":"2025","journal-title":"Rheumatology (Oxford, England), long\u2010Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2\u2010Year Results From Two Phase 3 Studies"},{"issue":"2","key":"e_1_2_15_29_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in Active Ankylosing Spondylitis: Results of the 2\u2010Year, Double\u2010Blind, Placebo\u2010Controlled SELECT\u2010AXIS 1 Study and Open\u2010Label Extension","volume":"8","author":"Heijde D.","year":"2022","journal-title":"RMD Open"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4037-y"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.2890"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0123-5"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu132"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40753"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00402-x"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40753"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-03897-w"},{"issue":"8","key":"e_1_2_15_44_1","first-page":"864","article-title":"Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta\u2010Analysis of Randomized Controlled Trials","volume":"306","author":"Ryan C.","year":"2011","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103267"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1247"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.227629"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.229997"},{"issue":"6","key":"e_1_2_15_49_1","first-page":"8880","article-title":"Association Between the TNF\u2010\u03b1 G\u2010308A Polymorphism and Risk of Ischemic Heart Disease: A Meta\u2010Analysis","volume":"8","author":"Wang J.","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2005"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00138-8"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086777"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.8.3.203"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24025"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185x.70573","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185x.70573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:34:58Z","timestamp":1773005698000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185x.70573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/1756-185x.70573"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.70573","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70573"}}